Welcome to our dedicated page for Veracyte SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Veracyte, Inc. (Nasdaq: VCYT) SEC filings, offering a detailed view into the company’s financial reporting, governance decisions, and key disclosures. Veracyte is a global cancer diagnostics and genomic testing company whose filings reflect its activities in developing and commercializing tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, as well as research platforms like Afirma GRID and Decipher GRID.
Investors can review Veracyte’s periodic reports on Forms 10-K and 10-Q for information about revenue composition, testing volumes, cost structure, and risk factors. Current reports on Form 8-K capture specific events, such as the release of quarterly financial results or shareholder votes. For example, recent 8-K filings describe quarterly earnings press releases and the approval of amendments to the company’s equity incentive plan, along with voting outcomes at the annual meeting of stockholders.
These filings also discuss Veracyte’s use of non-GAAP financial measures, including adjusted EBITDA and adjusted EBITDA margin, and explain which items are excluded from these metrics, such as amortization of acquired intangible assets, acquisition-related expenses, stock-based compensation, and certain restructuring costs. This context helps readers understand how management evaluates the company’s performance relative to GAAP results.
On Stock Titan, Veracyte filings are updated in near real time as they are posted to the SEC’s EDGAR system. AI-powered summaries highlight the main points of lengthy documents, helping users quickly identify key topics such as revenue trends, test portfolio updates, equity plan changes, and shareholder voting results. Users can also monitor forms that may relate to insider activity and executive compensation through the company’s proxy and related disclosures, using the AI tools to navigate complex regulatory language more efficiently.
Veracyte Inc. ownership filing: The Vanguard Group filed an amendment to its Schedule 13G/A reporting 0 shares beneficially owned and 0% of common stock following an internal realignment.
The filing states certain Vanguard subsidiaries will report separately in reliance on SEC Release No. 34-39538 (January 12, 1998), and that Vanguard no longer is deemed to beneficially own securities held by those subsidiaries. The amendment is signed by Vanguard's Head of Global Fund Administration on 03/27/2026.
VERACYTE, INC. filed an initial insider ownership report for Kevin Richard Haas, who serves as Chief Development and Technology Officer. This Form 3 establishes his status as a reporting officer under SEC rules. The filing does not list any buy, sell, or other share transactions, focusing instead on his reporting obligation as a company insider.
Veracyte, Inc. appointed Dr. Kevin Haas, 40, as Chief Development and Technology Officer, effective March 24, 2026. He previously served as Chief Technology Officer and in senior technology and bioinformatics roles at Myriad Genetics and its women’s health business.
Under his offer letter dated March 13, 2026, Dr. Haas will receive an initial annual base salary of $500,000 and will be eligible for an annual performance-based cash bonus targeted at 55% of eligible annual earnings, with his 2026 bonus prorated based on his start date.
He is also slated to receive a restricted stock unit award with a target value of $1,500,000 vesting over four years and a performance-based restricted stock unit award with a target value of $1,500,000, subject to performance objectives and continued service, all under Veracyte’s 2023 Equity Incentive Plan.
Wygant Jonathan reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. reported that its VP and Chief Accounting Officer, Jonathan Wygant, received an equity award in the form of 10,525 shares of common stock on March 6, 2026. The shares were granted at no cash cost to him as part of compensation.
According to the award terms, these restricted stock units vest 25% on March 2, 2027, then 1/16 of the grant vests each quarter after that date, subject to his continued employment on each vesting date. Following this award, he directly holds 45,434 shares of Veracyte common stock.
McGuire Annie reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. reported that SVP and General Counsel Annie McGuire received two equity grants of common stock on March 6, 2026, both at no cash cost to her. Following these awards, she directly holds 153,912 shares.
The first grant of 32,892 restricted stock units vests 25% on March 2, 2027 and then 1/16 each quarter, subject to her continued employment on each vesting date. The second grant of 26,314 restricted stock units vests in full on the first anniversary of the grant, also contingent on continued employment.
Febbo Phillip G. reported acquisition or exercise transactions in this Form 4 filing.
Veracyte, Inc. reported that Chief Scientific & Med Officer Phillip G. Febbo received equity awards in the form of common stock on March 6, 2026. He was granted 29,603 shares and an additional 6,578 shares, both at no cash cost to him.
According to the footnotes, the first award, structured as restricted stock units, vests 25% on March 2, 2027 and then 1/16 each quarter, subject to continued employment. The second award vests in full on the first anniversary of the grant date, also contingent on his continued employment. Following these grants, he directly owns 153,527 shares of Veracyte common stock.
Leite John reported acquisition or exercise transactions in this Form 4 filing.
Veracyte, Inc. reported an equity compensation grant to Chief Commercial Officer-CLIA John Leite. On March 6, 2026, he received two awards of Common Stock totaling 36,181 and 6,578 shares at $0.00 per share as grants rather than open-market purchases or sales. These awards are structured as restricted stock units that vest over time, including a schedule with 25% vesting on March 2, 2027 and quarterly thereafter, and another grant vesting in full on the first anniversary of the grant date, subject to continued employment. Following these transactions, Leite directly owns 150,339 shares of Veracyte common stock.
Stapley Marc reported acquisition or exercise transactions in this Form 4 filing.
VERACYTE, INC. reported that Chief Executive Officer Marc Stapley received a grant of 92,099 shares of common stock on March 6, 2026, in the form of restricted stock units. These RSUs vest 25% on March 2, 2027 and 1/16 each quarter thereafter, subject to his continued employment. Following this award, he directly holds 449,653 shares.
Chambers Rebecca reported acquisition or exercise transactions in this Form 4 filing.
Veracyte, Inc. Chief Financial Officer Rebecca Chambers reported two equity compensation awards in the form of restricted stock units tied to shares of common stock. She was granted 36,181 units and 13,157 units on March 6, 2026, both at no purchase price.
Following these awards, Chambers directly holds 180,534 shares of Veracyte common stock. One award vests 25% on March 2, 2027, with the remainder vesting in equal quarterly installments, while the other vests in full on the first anniversary of the grant, in each case conditioned on continued employment through the vesting dates.
VERACYTE, INC. Chief Financial Officer Rebecca Chambers reported selling a total of 18,341 shares of common stock in open-market transactions on March 4, 2026. The sales were made under a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2025.
The transactions were executed at weighted average prices of $35.5476 and $36.3288 per share, with sale price ranges disclosed in the footnotes. Following these sales, the reporting person directly owned 131,196 shares of Veracyte common stock.